Evidence map›Paper›PMID 34804041›Full record

ArticleFrontiers in immunology2021

Delivery of IL-2 to the T Cell Surface Through Phosphatidylserine Permits Robust Expansion of CD8 T Cells.

Alana MacDonald, Brandon Lam, John Lin, Louise Ferrall, Yu Jui Kung, Ya Chea Tsai, T-C Wu, Chien-Fu Hung

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Integrin Targeting Enhances the Antimelanoma Effect of Annexin V in Mice.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Alana MacDonaldGraduate Program in Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Brandon LamGraduate Program in Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
John LinDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Louise FerrallDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Yu Jui KungDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Ya Chea TsaiDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
T-C WuDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Chien-Fu HungDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI Richard Bruce Roden · 2003 to 2026
$53.5M
Mouse modeling of HPV infectionR01CA233486 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU, RODEN, RICHARD BRUCE · 2019 to 2023
$3.0M
Novel immunotherapeutic regimen combining the dendritic cell expansion power of Albumin-Flt3L and inflammatory cues of SalmonellaR21DE029910 · NIDCR · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2020 to 2021
$450k
Albumin-FMS-like tyrosine kinase 3 ligand (Alb-Flt3L) fusion protein as a novel adjuvant to enhance the immunogenicity and therapeutic and prophylactic efficacies of a HPV protein vaccineR21CA234516 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2020 to 2021
$421k
The role of Albumin-Flt3L-induced cross-presenting dendritic cell expansion in antitumor immunityF31CA236051 · NCI · JOHNS HOPKINS UNIVERSITY · PI LAM, BRANDON KRISHNA · 2019 to 2021
$128k
NCI NIH HHS F31 CA236051NCI NIH HHS P50 CA098252NCI NIH HHS R01 CA233486NCI NIH HHS R21 CA234516NIDCR NIH HHS R21 DE029910
6 · The paper itself

Abstract

The phospholipid phosphatidylserine (PS) is naturally maintained on the cytoplasmic side of the plasma membrane. Independent of apoptosis, PS is redistributed to the surface of CD8 T cells in response to TCR-mediated activation. Annexin V (AnnV) is a protein known to bind PS with high affinity and has been effectively utilized to anchor antigen to the surface of CD8 T cells. To expand these studies, we aimed to exploit TCR activation driven PS exposure as a target to deliver cytokine, namely interleukin-2 (IL-2), to the surface of CD8 T cells. This was accomplished using a novel chimeric fusion protein of annexin V and interleukin 2 (AnnV-IL2).

Indexed as

AnimalsAnnexin A5CD8-Positive T-LymphocytesFemaleInterleukin-2Lymphocyte ActivationMiceMice, TransgenicPhosphatidylserinesRecombinant Fusion ProteinsAnnexin A5Interleukin-2PhosphatidylserinesRecombinant Fusion Proteinsactivationannexin VCD8 T cellsinterleukin 2 (IL 2)phosphatidylserine (PS)

Identifiers

PMID34804041
PMCPMC8599986
OpenAlexW3212607037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.